Antara (Micronized) is owned by Lupin.
Antara (Micronized) contains Fenofibrate.
Antara (Micronized) has a total of 2 drug patents out of which 0 drug patents have expired.
Antara (Micronized) was authorised for market use on 30 November, 2004.
Antara (Micronized) is available in capsule;oral dosage forms.
Antara (Micronized) can be used as treating severe hypertriglyceridemia; treating primary hypercholesterolemia and mixed dyslipidemia, treating primary hypercholesterolemia and mixed dyslipidemia; treating severe hypertriglyceridemia.
The generics of Antara (Micronized) are possible to be released after 31 May, 2033.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8026281||LUPIN||Treating metabolic syndrome with fenofibrate|| |
(2 years from now)
|US9314447||LUPIN||Reduced dose pharmaceutical compositions of fenofibrate|| |
(10 years from now)
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic